In Phase A, contributors will receive unique doses and schedules of oral ABBV-744 pill to recognize Harmless dosing regimen. Added contributors will likely be enrolled within the determined monotherapy dosign program. In Phase B, participants will obtain oral ruxolitinib and ABBV-744 will probably be supplied as "add-on" therapy. In Segment https://richardb887zvt1.oblogation.com/profile